Skip to main content

FDA Approvals

Payers' Guide, FDA Approvals
Zykadia (Ceritinib) Approved for Patients with Crizotinib-Resistant ALK-Positive Non–Small-Cell Lung Cancer
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals, Payers' Guide
Once-Fatal Conditions Have Become Chronic: Early Trends in the FDA’s 2015 Approvals
Gary Branning, MBA
Read More
Payers' Guide, FDA Approvals
Glyxambi (Empagliflozin/Linagliptin): A Dual- Acting Oral Medication Approved for the Treatment of Patients with Type 2 Diabetes
Lisa A. Raedler, PhD, RPh
Read More
Payers' Guide, FDA Approvals
Lenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved by the FDA for the Treatment of Patients with Differentiated Thyroid Cancer
Loretta Fala
Read More
Payers' Guide, FDA Approvals
Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals
Idelalisib Approved for 3 Types of Hematologic Cancers
Read More
FDA Approvals
Belinostat Approved for Peripheral T-Cell Lymphoma
Read More
FDA Approvals
Palonosetron Indicated for CINV Prevention in Pediatric Patients
Read More
FDA Approvals
Zykadia for Metastatic, ALK-Positive Lung Cancer
Read More
FDA Approvals
Ramucirumab First Drug for Advanced Stomach Cancer
Read More
Page 44 of 53
Results 431 - 440 of 528